Frontiers in Pharmacology

Check for updates

Erratum: Wnt-pathway inhibitors with selective activity against triple-negative breast cancer: From thienopyrimidine to quinazoline inhibitors

Frontiers Production Office*

Frontiers Media SA, Lausanne, Switzerland

An Erratum on

Wnt-pathway inhibitors with selective activity against triple-negative breast cancer: From thienopyrimidine to quinazoline inhibitors

by Boudou C, Mattio L, Koval A, Soulard V and Katanaev VL (2022). Front. Pharmacol. 13:1045102. doi: 10.3389/fphar.2022.1045102

An omission to the **Funding** section of the original article was made in error. The following sentence has been added: "Open access funding was provided by the University of Geneva."

The original version of this article has been updated.